

1 **Seroprevalence of measles and varicella in healthcare workers in Chonburi province,**
2 **Thailand between October 2022 and January 2023**

3

4 Apirat Katanyutanon¹, Wichai Thanasophon¹, Chaninan Sonthichai², Piyada
5 Angsuwatcharakorn², Jira Chansaenroj³, Ratchathorn Nakabut⁴, Sarandhorn Naritpavalun⁴,
6 Yanathep Prasitsomsakul⁴, Paranyu Surakhot⁴, Phuvich Pompim⁴, Nasamon Wanlapakorn^{3,5},
7 Yong Poovorawan^{3,6*}

8

9 ¹ Chonburi Provincial Public Health Office, Bansuan, Mueang Chonburi, Chonburi, 20000,
10 Thailand.

11 ² Vaccine protection, Division of Communicable Diseases, Department of Disease Control,
12 Ministry of Public Health, Nonthaburi, Thailand

13 ³ Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,
14 Chulalongkorn University, Bangkok 10330, Thailand

15 ⁴ Secondary school, Triamudomsuksa School, Bangkok, Thailand

16 ⁵ Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University

17 ⁶ FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, 10300, Thailand

18

19 **Running head:** Seroprevalence of measles and varicella in healthcare workers

20 *Corresponding author

21 Address for correspondence: Yong Poovorawan, M.D. Center of Excellence in Clinical
22 Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,
23 Bangkok, Thailand. E-mail: yong.p@chula.ac.th

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract**

26 *Introduction:* Health care workers (HCWs) face the risk of contracting and transmitting
27 vaccine-preventable infectious diseases (VPDs). Therefore, it is crucial to evaluate the
28 immune status of HCWs against certain VPDs, such as measles and varicella zoster virus
29 (VZV). This study aimed to determine age-specific seropositivity rates of anti-measles and
30 anti-VZV IgG in HCWs working in Chonburi province, Thailand, and to develop a measles
31 and varicella vaccination policy for Thai HCWs.

32 *Methods:* A total of 266 HCWs in Chonburi Province, Thailand, were enrolled in this study
33 between October 2022 and January 2023. Participants were divided into six age groups: 21-
34 30, 31-40, 41-50, 51-60, 61-70, and >70 years. Anti-measles and anti-VZV IgG levels were
35 evaluated using commercial ELISA kits (EUROIMMUN, Lübeck, Germany).

36 *Results:* The overall seropositivity rates for measles and varicella were 85.0% and 81.2%,
37 respectively. The lowest seropositivity rates for both measles and varicella were found among
38 the 21-30-year-old group. Furthermore, seropositivity rates increased with age, reaching
39 100% among people over the age of 60 years.

40 *Conclusions:* To prevent measles and VZV outbreaks in HCWs, it is crucial to implement
41 catch-up measles and varicella vaccination programs, particularly among HCWs younger
42 than 30 years of age.

43 **Keywords:** Seroprevalence, Measles, Varicella, Healthcare workers

44

45

46

47

48

49

50 **Introduction**

51 Measles and varicella zoster virus (VZV) are extremely contagious diseases that
52 manifest with skin eruptions. The secondary attack rate of measles and varicella ranges
53 between 70% and 90% among susceptible exposed individuals [1]. The basic reproduction
54 number of measles and varicella ranges from 13 to 18 and 3.7 to 5.0, respectively [2, 3]. The
55 measles vaccine was developed in the 1970s and was integrated into the Expanded
56 Programme on Immunization (EPI) worldwide in 1974 [4]. The live attenuated varicella
57 vaccine, derived from the VZV Oka strain, has been licensed for more than a decade [5, 6].
58 Despite the decline in the incidence of measles and varicella resulting from widespread
59 vaccination efforts, outbreaks of these two diseases have been reported in settings where
60 children gather, such as childcare centers and schools, in hospitals, institutionalized children
61 and adults' facilities, refugee camps, and among healthcare workers (HCWs) [7-10].

62 HCWs are at increased risk for measles than the general population. In the United
63 States, 78 documented cases of measles were attributed to transmission within healthcare
64 facilities [11]. Furthermore, 29 healthcare personnel contracted the virus through
65 occupational exposure, with one individual transmitting the measles virus to a patient.
66 Consequently, the CDC's Advisory Committee on Immunization Practices (ACIP)
67 recommends that HCWs who were born before 1957 or who lack serological evidence of
68 immunity or prior vaccination should receive a two-dose regimen of the measles-mumps-
69 rubella (MMR) vaccine, with a minimum interval of four weeks between doses [12].

70 The VZV vaccine, also known as chickenpox vaccine, is a live-attenuated vaccine for
71 protection against chickenpox (varicella) [7, 13]. The currently licensed varicella vaccines are
72 highly effective in preventing varicella and its complications [14, 13]. However, varicella
73 outbreaks have been reported, including among healthcare workers in Thailand [15]. Previous
74 seroprevalence studies showed high levels of seronegativity among healthcare workers

75 ranging from 14–15.6% in Malaysia and Saudi Arabia, to as high as 51% among first-year
76 medical and engineering students in Sri Lanka [16-18]. In Thailand, the varicella vaccine is
77 an optional vaccine. Thus, the coverage is low. A previous study of VZV seroprevalence in
78 Thailand conducted among university students found that 26% were seronegative to anti-
79 VZV antibodies, suggesting that one in four young Thai adults remained susceptible to
80 varicella [19]. The CDC's ACIP recommends that for varicella, HCWs born after 1970,
81 without a history of varicella and/or a negative result on the antibody screening test, are
82 advised to receive a two-dose vaccination series.

83 To develop a measles and varicella vaccination policy for Thai HCWs, it is important
84 to understand the seroprevalence of these two diseases. Currently, there are neither
85 serological screening nor a catch-up vaccination campaign in the HCWs working in Chonburi
86 Province, Thailand. This study aimed to investigate the immune status of HCWs against
87 measles and varicella in a variety of healthcare settings located in Chonburi province,
88 Thailand and to define an appropriate vaccination program among HCWs.

89

90 **Methods**

91 *Study design and ethical considerations*

92 This cross-sectional study was part of the large-scale serosurvey conducted in 11
93 districts in Chonburi province, Thailand, between October 2022 and January 2023 [20]. In
94 the large-scale serosurvey, there was a total of 1193 general population and 266 HCWs. The
95 cluster random sampling method was used to enroll participants. The stratified clusters within
96 the 11 districts were divided into urban and rural strata. From each district, each cluster was
97 selected using the probability proportionate-to-size sampling method. Healthcare workers
98 were selected from distinct-level health facilities within each district using consecutive

99 sampling in each district. In the present study, only serological samples from 266 HCWs
100 were analyzed.

101 The protocol received approval from the Institutional Review Board of the Faculty of
102 Medicine of Chulalongkorn University (IRB numbers 0706/65). This study adhered to the
103 ethical principles stated in the Declaration of Helsinki and followed the principles of good
104 clinical practice. Prior to their participation in the study, written consent was obtained from
105 each participant.

106
107 *Participants and Sample Collection*

108 HCWs were approached for eligibility. Exclusion criteria included aged <18 years or
109 > 80 years, having immunosuppressive disorders, malignancy, or diseases that require
110 immunosuppressive agents. A structured questionnaire was applied to voluntary HCWs. The
111 data collected in this study included age, sex, history of measles and varicella infection, and
112 previous vaccination.

113 Blood samples of 3-5 milliliters (mL) were collected and subsequently subjected to
114 centrifugation to obtain serum samples, which were aliquoted and stored at -20°C until further
115 laboratory tests.

116
117 *Laboratory testing*

118 *Seroprevalence of Measles and VZV*

119 Commercial enzyme-linked immunosorbent assay (ELISA) kits were used according
120 to the manufacturer's instructions to measure IgG concentrations against measles and VZV
121 (EURROIMMUN, Lubeck, Germany). Serum samples were initially diluted 1:100 and then
122 further diluted to obtain values within the detection range. Anti-measles and anti-VZV IgG

123 concentrations are expressed in international units per liter (IU/L). The cut-off for
124 seropositivity and seroprotection rate against measles in this study was ≥ 275 IU/L. The cut-
125 off for seropositivity and seroprotection rate against varicella in this study was ≥ 110 IU/L.

126
127 *Statistical Analysis*

128 Data on the seropositivity rates of anti-measles IgG and anti-VZV IgG are presented
129 as numbers and percentages. Geometric mean titers (GMT) were calculated. The associations
130 between sex and GMT were performed using Person's chi-square test. Comparison of
131 logarithmic-transformed GMTs between groups was compared using one-way ANOVA. All
132 statistical analyses were performed with SPSS v23.0 (IBM Corp., Chicago, IL). Figures were
133 generated using GraphPad Prism v9.4.1 (GraphPad Software, San Diego, CA). A *p*-
134 value < 0.05 was considered statistically significant.

135

136 **Results**

137 *Demographic characteristics of study participants*

138 In this study, a total of 266 HCWs were included for the seroprevalence studies of
139 measles and varicella. The mean age was 38.3 years (Table 1). There were more female than
140 male participants in this study (77.8% female versus 22.2% male). Most of the HCWs were
141 between 21-30 years old, followed by 31-40 years and 41-50 years old. Only 5.6% of the
142 HCWs (15/266) indicated that they had contracted measles, while 21.8% (58/266) reported
143 having been vaccinated against measles. On the contrary, up to 48.1% (128/266) indicated
144 that they had contracted varicella, while only 4.9% (13/266) reported having been vaccinated
145 against varicella.

146 *Seroprotection rates and GMTs against measles and VZV in healthcare workers*

147 Table 2 shows the proportion of HCWs who achieved seroprotection rates against
148 measles and their GMTs by age groups. Overall, 85% of the HCWs in this study had an anti-
149 measles IgG of > 275 IU/L with a GMT of 1128.0 (964.5 – 1320.0) IU/L. A high
150 seroprotection rate (>98%) was observed in older individuals 41 years of age. The lowest
151 seroprotection rate was found among HCWs in the age group of 21–30 years (68.2%).
152 HCWs in the 41-50- and 51-60-year-old age groups had significantly higher anti-measles IgG
153 GMTs than the 21-30-old age group as shown in Table 2 (p -value < 0.001). There were no
154 significant differences in GMT between male and female HCWs (p -value = 0.457).

155 Table 3 shows the proportion of HCWs who achieved the seroprotection rate against
156 varicella and their GMTs by age groups. A total of 81.2% (216/266) of HCWs achieved a
157 seroprotection rate against varicella, with a GMT of 394.0 (315.4-492.0) IU/L. Similar to
158 measles, a high seroprotection rate (>90%) was observed in older individuals from 41 years
159 of age. The lowest seroprotection rate for varicella was also found among HCWs in the 21–
160 30-year-old age group (64.8%). HCWs in the 41-50- and 51-60-year-old age groups had
161 significantly higher anti-VZV IgG GMTs than the 21-30-old age group as shown in Table 3
162 (p -value < 0.05). No significant differences in the seroprotection rate were found between
163 male and female HCWs (p -value = 0.508). In particular, the seroprotection rate against
164 measles and VZV gradually increased with age and reached 100% in HCWs over 60 years of
165 age.

166 *Correlation between serological results and self-reported medical history.*

167 Table 4 shows the correlation between the seroprotection rates against measles and
168 VZV and the history of previous vaccination and infection. HCWs with a self-reported
169 history of previous measles infection or vaccination had protective levels of anti-measles IgG
170 in 86.7-89.7% of cases, but not significantly higher than in those who did not report previous
171 infection or vaccination. On the contrary, a history of previous varicella was more frequent

172 among those who were immune to varicella (p -value = 0.018) than among those who were
173 susceptible. HCWs who reported having no previous vaccination against varicella were more
174 likely to be immune (p -value < 0.001), suggesting that the positive serological results were
175 due to natural infection. The positive predictive value of the history of varicella was 89.84%,
176 where it was 86.67% for the history of measles (Table 5). The positive predictive value of the
177 history of varicella vaccination was 76.92%, where it was 89.66% for the history of measles
178 vaccination. The negative predictive value of the was low for both measles and varicella
179 infection and vaccination in this study.

180

181 **Discussion**

182 Vaccination for HCWs is an essential step in protecting not only HCWs but also
183 patients and communities [21, 22]. To establish an effective immunization program, a
184 serological survey is necessary to obtain the immune status of HCWs, together with a history
185 of previous infection and vaccination, are necessary. Our study showed high seroprotection
186 rates of more than >90% for measles (anti-measles IgG > 275 IU/L) and VZV (anti-VZV IgG
187 > 110 IU/L) in HCWs older than 41 years working in Chonburi Province, Thailand, even
188 when the policy for the screening and vaccination campaign in HCWs has not been
189 implemented. This preexisting immunity is likely to result from natural exposure before the
190 EPI for measles and varicella vaccinations were in place for all infants. On the contrary,
191 individuals between 21-30 years of age who were born under the universal measles
192 vaccination for all infants at 9 months of age had the lowest seroprotection rate for measles.
193 A recent seroprevalence survey in Thai adolescents also showed that, despite 70%
194 documented one- or two-dose measles vaccination during childhood, only half of the
195 adolescents had anti-measles IgG greater than 275 IU/L, likely due to the decline of
196 antibodies without natural exposure or primary vaccine failure [23]. Thus, in this study,

197 HCWs younger than 30 years of age who could have been vaccinated against measles under
198 the EPI program could possibly have anti-measles immunity that waned overtime.
199 Furthermore, the second dose of measles-containing vaccine coverage among Thai children
200 reached more than 80% of the population only after 2016, suggesting that a large number of
201 populations may have received only one dose of measles-containing vaccine during
202 childhood [24]. Thus, it is important to prioritize a catch-up campaign for measles
203 vaccination for young healthcare workers who had no history of two-dose measles
204 immunization or had negative serology.

205 In the present study, the overall seroprotection rate for measles in HCWs was lower
206 than in the general population over 26 years of age in our previous serosurvey conducted in
207 2014 (85% versus 97.7%) [25]. The younger generation of the 2030s, having been born under
208 the Expanded Program on Immunization (EPI) with improved vaccine coverage, may possess
209 vaccine-induced immunity that diminishes over time, resulting in lower seroprevalence rates
210 during adulthood compared to the previous survey 10 years ago. Additionally, comparison of
211 anti-measles seroprevalence among HCWs from different regions showed that HCWs from
212 high-income countries had a higher rate of measles seroprevalence ranging from 87% to 97%
213 than HCWs in our study [9].

214 Our study showed that the overall seroprotection rate against varicella was 81.2%
215 This rate was lower compared to HCWs in Japan (96.3%) [26], Finland (99%) [27], Denmark
216 (98.6%) [28], and Korea (91%) [29, 30]. In Thailand, older individuals acquired immunity to
217 varicella through natural exposure, while younger individuals may have received varicella
218 vaccination, which are optional vaccines, or may have contracted the disease during
219 childhood. Therefore, younger HCWs are likely to have a low seroprotection rate compared
220 to older HCWs due to the low coverage of optional vaccines and the lack of exposure to
221 natural infection. Other countries also reported low anti-VZV seroprevalence rates in the

222 young population [31]. Based on our results, it is recommended to prioritize varicella
223 vaccination for HCWs in the 21-30 age group with negative serology and no record of two-
224 dose varicella vaccination.

225 The correlation between self-reported history and seroprotected status showed that
226 neither history of measles vaccination nor history of measles were associated with
227 seroprotected status. Our results are consistent with other studies showing that self-reported
228 vaccination history may not be predictive and reliable [27]. Therefore, when a measles
229 vaccination record was not available, serologic tests should be performed to provide evidence
230 of measles immunity. Unlike measles, we found that a history of previous varicella was more
231 frequent among those who were immune to varicella. This is similar to the report of a Thai
232 university student showing the significant association between the history of varicella and the
233 seropositivity rate [19]. Consistent with a previous report, negative predictive values for both
234 previous vaccination and infection were very low for both measles and varicella [30]. Our
235 research indicates the necessity of implementing a universal record system to document
236 vaccine administration for every individual in Thailand. The universal record system could
237 potentially reduce unnecessary serologic screening and catch-up vaccinations.

238 This study has some limitations. First, the participants' history of vaccination and
239 previous infection was only obtained through questionnaires, which resulted in missing
240 information and uncertain information regarding diagnosis, actual vaccination doses, and
241 dates. Selecting HCWs from one province may not fully represent all HCWs in Thailand. A
242 larger study that explores other regions of Thailand could provide a more comprehensive
243 representation of the entire country. Additionally, the small sample size of participants older
244 than 60 years makes it challenging to draw conclusive results.

245

246 **Conclusions**

247 This study provides comprehensive information to inform policy makers and establish
248 effective measles and varicella immunization programs for HCWs throughout the country. To
249 prevent measles and VZV outbreaks in HCWs, it is crucial to conduct serological screening
250 and implement catch-up measles and varicella vaccination programs, particularly among
251 HCWs younger than 30 years of age.

252

253 **Acknowledgements**

254 We greatly appreciate the kind contributions and collaboration of all participants. With all of
255 their help, the interesting information obtained from this study could be used for the future
256 development of vaccine strategies. We thank all staff from the hospitals in Chonburi Province
257 for enrolling participants and staff from the Center of Excellence in Clinical Virology,
258 Faculty of Medicine, Chulalongkorn University, for their help with the laboratory testing.

259

260 **Ethics approval**

261 The study protocol was reviewed and approved by the Institutional Review Board (IRB),
262 Faculty of Medicine, Chulalongkorn University (IRB 0706/65). Written informed consent
263 was waived by the IRB.

264

265 **Conflict of interest statement**

266 The authors have no conflict of interest to declare.

267

268 **Funding**

269 This research was financially supported by the Health Systems Research Institute (HSRI), the
270 National Research Council of Thailand (NRCT), the Research Chair Grant from the National
271 Science and Technology Development Agency (P-15-50004), the Center of Excellence in

272 Clinical Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital
273 and the Second Century Fund (C2F) of Jira Chansaenroj, Chulalongkorn University. The
274 funders had no role in study design, data collection, analysis, publication decision, or
275 manuscript preparation.

276

277 **Author contributions**

278 Conceptualization: Y.P.; Data curation: A.K., W.T., J.C., N.W.; Formal analysis: A.K., J.C.,
279 N.W.; Funding acquisition: J.C., Y.P.; Investigation: A.K., W.T.; Methodology: A.K., J.C.;
280 Project administration: J.C., R.N., S.N., Y.P., P.S., P.P.; Resources: A.K., W.T., C.S., P.A.;
281 Software: J.C., N.W.; Supervision: Y.P.; Validation: A.K., N.W., Y.P.; Visualization: J.C.;
282 Roles/Writing - original draft: A.K., J.C., R.N., S.N., Y.P., P.S., P.P., N.W. ;and Writing –
283 review & editing: A.K., N.W.

284

285 **Data availability statement**

286 The authors confirm that all data supporting the findings of this study are available within the
287 article.

288

289 **References**

290

- 291 [1] Lee JS, Jeong O, Yang H. Screening and Vaccination Against Measles and Varicella
292 Among Health Care Workers: A Cost-effectiveness Analysis. *Asia Pac J Public*
293 *Health*. 2021 Jul;33(5):508-515. doi: 10.1177/10105395211026468. Epub 2021 Jun
294 24. PMID: 34165349.
- 295 [2] Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic
296 reproduction number (R(0)) of measles: a systematic review. *Lancet Infect Dis*. 2017

- 297 Dec;17(12):e420-e428. doi: 10.1016/S1473-3099(17)30307-9. Epub 2017 Jul 27.
- 298 PMID: 28757186.
- 299 [3] Marangi L, Mirinaviciute G, Flem E, Scalia Tomba G, Guzzetta G, Freiesleben de
300 Blasio B, et al. The natural history of varicella zoster virus infection in Norway:
301 Further insights on exogenous boosting and progressive immunity to herpes zoster.
302 PLoS One. 2017;12(5):e0176845. doi: 10.1371/journal.pone.0176845. PMID:
303 28545047; PMCID: PMC5436649.
- 304 [4] Okwo-Bele JM, Cherian T. The expanded programme on immunization: a lasting
305 legacy of smallpox eradication. *Vaccine*. 2011 Dec 30;29 Suppl 4:D74-79. doi:
306 10.1016/j.vaccine.2012.01.080. PMID: 22486980.
- 307 [5] Hinman A. Eradication of vaccine-preventable diseases. *Annu Rev Public Health*.
308 1999;20:211-229. doi: 10.1146/annurev.publhealth.20.1.211. PMID: 10352857.
- 309 [6] Arvin AM, Greenberg HB. New viral vaccines. *Virology*. 2006 Jan 5;344(1):240-249.
310 doi: 10.1016/j.virol.2005.09.057. PMID: 16364754.
- 311 [7] Gershon AA. Viral vaccines of the future. *Pediatr Clin North Am*. 1990
312 Jun;37(3):689-707. doi: 10.1016/s0031-3955(16)36911-5. PMID: 2161508.
- 313 [8] Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term
314 effectiveness of varicella vaccine: a 14-Year, prospective cohort study. *Pediatrics*.
315 2013 May;131(5):e1389-96. doi: 10.1542/peds.2012-3303. Epub 2013 Apr 1. PMID:
316 23545380.
- 317 [9] Haviari S, Benet T, Saadatian-Elahi M, Andre P, Loulergue P, Vanhems P.
318 Vaccination of healthcare workers: A review. *Hum Vaccin Immunother*.
319 2015;11(11):2522-2537. doi: 10.1080/21645515.2015.1082014. PMID: 26291642;
320 PMCID: PMC4685699.

- 321 [10] Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress
322 Toward Regional Measles Elimination - Worldwide, 2000-2021. *MMWR Morb*
323 *Mortal Wkly Rep.* 2022 Nov 25;71(47):1489-1495. doi: 10.15585/mmwr.mm7147a1.
324 PMID: 36417303; PMCID: PMC9707362.
- 325 [11] Fiebelkorn AP, Redd SB, Kuhar DT. Measles in Healthcare Facilities in the United
326 States During the Postelimination Era, 2001-2014. *Clin Infect Dis.* 2015 Aug
327 15;61(4):615-618. doi: 10.1093/cid/civ387. Epub 2015 May 15. PMID: 25979309;
328 PMCID: PMC4646220.
- 329 [12] Advisory Committee on Immunization P, Centers for Disease C, Prevention.
330 Immunization of health-care personnel: recommendations of the Advisory Committee
331 on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2011 Nov 25;60(RR-7):1-
332 45. PMID: 22108587.
- 333 [13] Weinmann S, Naleway AL, Koppolu P, Baxter R, Belongia EA, Hambidge SJ, et al.
334 Incidence of Herpes Zoster Among Children: 2003-2014. *Pediatrics.* 2019 Jul;144(1).
335 doi: 10.1542/peds.2018-2917. Epub 2019 Jun 10. PMID: 31182552; PMCID:
336 PMC7748320.
- 337 [14] Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, et al.
338 Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged
339 ≥ 50 years: A prospective study. *Prev Med Rep.* 2019 Jun;14:100882. doi:
340 10.1016/j.pmedr.2019.100882. PMID: 31193254; PMCID: PMC6522697.
- 341 [15] Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P,
342 Mundy LM. Outbreak of varicella-zoster virus infection among Thai healthcare
343 workers. *Infect Control Hosp Epidemiol.* 2007 Apr;28(4):430-434. doi:
344 10.1086/512639. Epub 2007 Feb 26. PMID: 17385149.

- 345 [16] Almuneef MA, Memish ZA, Balkhy HH, Otaibi B, Helmi M. Seroprevalence survey
346 of varicella, measles, rubella, and hepatitis A and B viruses in a multinational
347 healthcare workforce in Saudi Arabia. *Infect Control Hosp Epidemiol.* 2006
348 Nov;27(11):1178-1183. doi: 10.1086/508826. Epub 2006 Oct 17. PMID: 17080374.
- 349 [17] Sam IC, Tariman H, Chan YF, Bador MK, Yusof MY, Hassan H. Varicella-zoster
350 virus seroprevalence in healthcare workers in Kuala Lumpur, Malaysia. *Med J*
351 *Malaysia.* 2008 Dec;63(5):429-430. PMID: 19803311.
- 352 [18] Kurukulasooriya GM, Thevanesam V, Agampodi SB, Abeykoon AM, Amarasiri SP,
353 Goonasekera KP. Susceptibility of New Entrant University students in Sri Lanka to
354 varicella zoster infection. *Asia Pac J Public Health.* 2010 Apr;22(2):219-224. doi:
355 10.1177/1010539509334625. Epub 2009 May 1. PMID: 19411280.
- 356 [19] Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa V.
357 Prevalence of anti-varicella zoster IgG antibody in undergraduate students. *Asian Pac*
358 *J Allergy Immunol.* 1996 Dec;14(2):129-31. PMID: 9177828.
- 359 [20] Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Vichaiwattana P,
360 Klinfueng S, et al. Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-
361 RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October
362 2022 to January 2023. *Sci Rep.* 2023 Sep 20;13(1):15595. doi: 10.1038/s41598-023-
363 42754-2. PMID: 37730917; PMCID: PMC10511501.
- 364 [21] Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine
365 hesitancy and healthcare providers. *Vaccine.* 2016 Dec 20;34(52):6700-06. doi:
366 10.1016/j.vaccine.2016.10.042. Epub 2016 Oct 31. PMID: 27810314.
- 367 [22] Gaviola GC, McCarville M, Shendale S, Goodman T, Lomazzi M, Desai S. A review
368 of health worker vaccination programs in low, middle and upper middle-income

- 369 countries. *Public Health Pract (Oxf)*. 2023 Dec;6:100415. doi:
370 10.1016/j.puhip.2023.100415. PMID: 37547811; PMCID: PMC10400463.
- 371 [23] Puthanakit T, Anugulruengkitt S, Angsuwatcharakon P, Bunjoungmanee P,
372 Kowitdamrong E, Primsirikunawut A, et al. Low Measles Seropositivity Rate among
373 Thai Adolescents in the Thai National Immunization Program. *Vaccines (Basel)*. 2022
374 Aug 6;10(8). doi: 10.3390/vaccines10081269. PMID: 36016157; PMCID:
375 PMC9412740.
- 376 [24] Measles vaccination coverage. World Health Organization: World Health
377 Organization; 2023. Available from:
378 <https://immunizationdata.who.int/pages/coverage/mcv.html?CODE=SEAR&ANTIGE>
379 [N=MCV2&YEAR=](https://immunizationdata.who.int/pages/coverage/mcv.html?CODE=SEAR&ANTIGE)
- 380 [25] Wanlapakorn N, Wasitthankasem R, Vichaiwattana P, Auphimai C, Yoocharoen P,
381 Vongpunsawad S, et al. Antibodies against measles and rubella virus among different
382 age groups in Thailand: A population-based serological survey. *PLoS One*.
383 2019;14(11):e0225606. doi: 10.1371/journal.pone.0225606. PMID: 31770412;
384 PMCID: PMC6879141.
- 385 [26] Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M.
386 Seroprevalence survey on measles, mumps, rubella and varicella antibodies in
387 healthcare workers in Japan: sex, age, occupational-related differences and vaccine
388 efficacy. *Epidemiol Infect*. 2014 Jan;142(1):12-9. doi: 10.1017/S0950268813000393.
389 Epub 2013 Apr 11. PMID: 23574767; PMCID: PMC3857110.
- 390 [27] Koivisto K, Puhakka L, Lappalainen M, Blomqvist S, Saxen H, Nieminen T.
391 Immunity against vaccine-preventable diseases in Finnish pediatric healthcare
392 workers in 2015. *Vaccine*. 2017 Mar 14;35(12):1608-14. doi:
393 10.1016/j.vaccine.2017.02.018. Epub 2017 Feb 21. PMID: 28233625.

- 394 [28] von Linstow ML, Yde Nielsen A, Kirkby N, Eltvedt A, Nordmann Winther T, Bybeck
395 Nielsen A, et al. Immunity to vaccine-preventable diseases among paediatric
396 healthcare workers in Denmark, 2019. *Euro Surveill.* 2021 Apr;26(17). doi:
397 10.2807/1560-7917.ES.2021.26.17.2001167. PMID: 33928900; PMCID:
398 PMC8086246.
- 399 [29] Yun JH, Lee E, Choi JH, Ki HK, Park J. Seroprevalence of Varicella-Zoster Virus
400 and Measles among Healthcare Workers in a Tertiary Medical Center in Korea.
401 *Vaccines (Basel)*. 2022 Nov 18;10(11). doi: 10.3390/vaccines10111956. PMID:
402 36423051; PMCID: PMC9697537.
- 403 [30] Shin L, Choi JR, Huh K, Chung DR, Cho SY, Jeong J, et al. Trend of immunity
404 against measles and varicella zoster virus in healthcare workers in Korea. *Vaccine*.
405 2023 Jul 19;41(32):4679-84. doi: 10.1016/j.vaccine.2023.06.018. Epub 2023 Jun 20.
406 PMID: 37349224.
- 407 [31] Yoo Y, Park WJ, Cho S, Lim DY, Kim S, Kang W, et al. Seroprevalence of measles,
408 mumps, rubella, and varicella-zoster antibodies in new female nurses in the Republic
409 of Korea. *Ann Occup Environ Med.* 2021;33:e19. doi: 10.35371/aoem.2021.33.e19.
410 PMID: 34754480; PMCID: PMC8264122.
- 411
412
413
414
415
416
417
418

419 **Table 1.** Demographic characteristics of the HCWs included in this study (N=266)

Mean age, years (SD)	38.3 (11.5)
Sex	N (%)
Male	59 (22.2)
Female	207 (77.8)
Past history of measles	N (%)
Yes	15 (5.6)
No	230 (86.5)
Uncertain	21 (7.9)
Previous vaccination against measles	N (%)
Yes	58 (21.8)
No	75 (28.2)
Uncertain	133 (50.0)
Past history of varicella	N (%)
Yes	128 (48.1)
No	122 (45.9)
Uncertain	16 (6.0)
Previous varicella vaccination	N (%)
Yes	13 (4.9)
No	149 (56.0)
Uncertain	104 (39.1)

420 SD = standard deviation

421

422

423 **Table 2.** Seroprevalence of anti-measles IgG in HCWs by age group and sex.

424

Variables	No.	Proportion of seroprotected individuals, N (%)	GMT (IU/L) (95% CI)	p-value (One-way ANOVA)
All	266	226 (85.0)	1128.0 (964.5 – 1320.0)	
Age groups (years)				
21-30	88	60 (68.2)	614.8 (454.5 – 831.7)	Reference
31-40	75	65 (86.7)	1036.5 (783.1 – 1372.0)	0.030
41-50	54	53 (98.1)	2095.8 (1584.0 – 2773.0)	<0.0001*
51-60	43	42 (97.7)	1969.9 (1512.0 – 2567.0)	<0.0001*
61-70	4	4 (100)	2135.1 (319.1 – 14285.0)	0.193
>70	2	2 (100)	1037.4 (2.1 – 522915.0)	0.976
Sex				
Male	59	52 (88.1)	1261 (935.7 – 1699.0)	0.457
Female	207	174 (84.1)	1093 (909.7 – 1313.0)	

425 GMT: Geometric mean titer, * = statistically significant

426

427 **Table 3.** Seroprevalence of anti-VZV IgG in HCWs by age group and sex

428

Variables	No.	Proportion of seroprotected individuals, N (%)	GMT (IU/L) (95% CI)	p-value (One-way ANOVA)
All	266	216 (81.2)	394.0 (315.4 – 492.0)	
Age groups (years)				
21-30	88	57 (64.8)	239.6 (148.6 – 386.2)	Reference
31-40	75	63 (84.0)	326.7 (213.8 – 499.1)	0.774
41-50	54	50 (92.6)	617.7 (436.3 – 874.4)	0.012*
51-60	43	40 (93.0)	791.4 (553.3 – 1132.0)	0.002*
61-70	4	4 (100)	767.1 (127.8 – 4605.0)	0.659
>70	2	2 (100)	616.3 (33.1 – 11461.0)	0.947
Sex				
Male	59	50 (84.7)	453.3 (268.2 – 766.0)	0.508
Female	207	166 (80.2)	378.5 (296.1 – 483.9)	

429 GMT: Geometric mean titer, * = statistically significant

430

431 **Table 4.** The Correlation between the serological results of anti-measles anti-VZV IgG with
432 the self-reported medical history.

433

Variables	Total (N=266)	Immune (seroprotected) N (%)	Nonimmune (susceptible) N (%)	p-value
Measles				
History of vaccination				0.064
Yes	58	52 (89.7)	6 (10.3)	
No	75	67 (89.3)	8 (10.7)	
Uncertain or N/A	133	107 (80.5)	26 (19.5)	
History of measles				0.864
Yes	15	13 (86.7)	2 (13.3)	
No	230	195 (84.8)	35 (15.2)	
Uncertain or N/A	21	18 (85.7)	3 (14.3)	
Varicella				
History of vaccination				<0.001*
Yes	13	10 (76.9)	3 (23.1)	
No	149	132 (88.6)	17 (11.4)	
Uncertain or N/A	104	74 (71.2)	30 (28.8)	
History of varicella				0.018*
Yes	128	115 (89.8)	13 (10.2)	
No	122	89 (73.0)	33 (27.0)	
Uncertain or N/A	16	12 (75.0)	4 (25.0)	

434 N/A: Data not available.

435

436 **Table 5.** Positive predictive values and negative predictive values of the self-reported history

437 of infection or vaccination.

438

		Positive predictive value (%)	Negative predictive value (%)
Measles	History of measles	86.67	15.22
	History of vaccination	89.66	10.67
Varicella	History of varicella	89.84	27.05
	History of vaccination	76.92	11.41

439

440